A Prospective, Open-label, Single-arm, Multi-Center, Phase II Trial of NOV120101 in Patients With HER2-overexpressed Recurrent Stage IV Breast Cancer Who Have Received at Least 2 Prior HER2-directed Regimens
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2016
At a glance
- Drugs Poziotinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 29 Feb 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 29 Feb 2016 Planned End Date changed from 1 Mar 2017 to 1 Feb 2017 as reported by ClinicalTrials.gov.
- 29 Feb 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Feb 2017 as reported by ClinicalTrials.gov.